Review
Hematology
Jennifer E. Amengual, Barbara Pro
Summary: Posttransplant lymphoproliferative disorder (PTLD) is a significant and potentially life-threatening complication of solid organ transplant and hematopoietic stem cell transplant (HSCT). Treatment of PTLD is challenging and includes methods such as immunosuppression reduction, immunotherapy, and chemotherapy. Novel treatments are needed for high-risk patients or those who do not respond to frontline therapies.
Review
Hematology
Alessandro Casini, Philippe de Moerloose
Summary: Congenital dysfibrinogenemia is a disorder caused by structural changes in fibrinogen, leading to bleeding tendencies and thrombosis. Most patients are asymptomatic at diagnosis and genetic testing is needed for confirmation. Treatment involves fibrinogen supplementation and the use of antifibrinolytic agents in certain clinical settings.
Review
Hematology
Jeffrey E. Rubnitz, Gertjan J. L. Kaspers
Summary: Treatment outcomes for pediatric patients with acute myeloid leukemia (AML) are behind those with acute lymphoblastic leukemia (ALL) due to disease heterogeneity, lack of targeted therapies, and slow development of immunotherapy. Further intensification of conventional chemotherapy is unlikely to reduce relapse rates, but comprehensive genomic analyses and understanding of leukemic stem cells may lead to more effective tailored therapies in the future. New therapies like venetoclax and CAR T-cell therapy offer hope for improved outcomes in pediatric AML treatment.
Article
Hematology
Ross Baker, James S. O'Donnell
Summary: Recent studies show an increasing frequency in the diagnosis of BDUC, with a need for consensus on clinical and laboratory criteria. Objective assessment of bleeding phenotype using BAT is crucial for the diagnosis of BDUC. Despite the high prevalence of BDUC, diagnosing and managing these patients present significant clinical dilemmas.
Review
Oncology
J. Taieb, M. Karoui, D. Basile
Summary: The key in treatment decision-making for stage II colon cancer lies in classifying tumors based on molecular and clinico-pathological features, then choosing appropriate treatment methods including surveillance, adjuvant therapy, and drug treatment. New tools in the future may help to more accurately identify patients for a more personalized treatment approach.
Article
Hematology
Giovanni Palladini, Giampaolo Merlini
Summary: The treatment of AL amyloidosis is a challenge for hematologists, but early diagnosis and personalized therapy can improve patient outcomes.
Review
Hematology
Brunangelo Falini, Lorenzo Brunetti, Maria Paola Martelli
Summary: Mutations of the nucleophosmin (NPM1) gene play a crucial role in adult acute myeloid leukemia (AML), with unique molecular, pathological, and clinical features. Accurate diagnosis and distinction of NPM1-mutated AML from other entities is important for guiding treatment decisions and assessing relapse risk. Monitoring measurable residual disease (MRD) using NPM1 mutations can provide valuable insights for therapeutic management after remission.
Review
Hematology
Robert A. Brodsky
Summary: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare complement-mediated hemolytic anemia with diverse manifestations, requiring differentiated treatment approaches; terminal complement inhibition is effective for intravascular hemolysis treatment but not bone marrow failure; novel complement inhibitors under clinical development show promising prospects for future applications.
Article
Hematology
Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos
Summary: Multiple myeloma is an incurable disease, and patients require long-term treatment. Despite the introduction of new therapies, drug resistance remains the most critical factor in choosing the appropriate treatment. Currently, three-drug regimens are the standard approach for managing relapsed disease.
Review
Hematology
Firas El Chaer, Christopher S. Hourigan, Amer M. Zeidan
Summary: The European LeukemiaNet has recently updated the clinical and measurable residual disease testing guidelines for acute myeloid leukemia (AML) in 2022 and 2021 respectively. These updates provide new recommendations for classification, risk stratification, prognostication, monitoring, and response assessment in AML patients. Advances in understanding the genetic drivers of AML and its biology have led to the development of novel therapies and more complex clinical treatment guidelines.
Article
Hematology
Simon J. Stanworth, Andrew D. Mumford
Summary: Neonatal thrombocytopenia is a common abnormality in babies admitted to neonatal intensive care units, with various potential causes including bacterial sepsis, viral infection, and genetic disorders. Accurate diagnosis is crucial for assessing adverse events and selecting appropriate treatments, such as platelet transfusion. Recent advances in genomic technology and clinical trials have influenced the landscape of diagnosis and management, with an increasing emphasis on judicious and restricted use of platelet transfusions.
Review
Hematology
Wilma Barcellini, Bruno Fattizzo
Summary: Warm autoimmune hemolytic anemia is a disease caused by increased destruction of red blood cells by IgG autoantibodies, with complex pathogenic mechanisms and unpredictable prognosis. Treatment options include steroids, splenectomy, immunosuppressants, and rituximab, but challenges exist in choosing and managing these therapies.
Article
Hematology
Elena Zamagni, Simona Barbato, Michele Cavo
Summary: This article discusses the definitions of high-risk multiple myeloma (MM), trial results, and risk-adapted treatment strategies. For difficult-to-treat patients, therapy should be tailored based on relevant risk factors and biological characteristics.
Review
Oncology
B. Kiesewetter, P. Riss, C. Scheuba, M. Raderer
Summary: Medullary thyroid cancer (MTC) is a rare neuroendocrine tumor that requires multidisciplinary management. Various oncogenic pathways are involved in MTC pathogenesis, and targeted therapies have shown promising results. Multikinase inhibitors such as vandetanib and cabozantinib have been approved for advanced MTC treatment.
Review
Oncology
A. Lamarca, J. Edeline, L. Goyal
Summary: Management of biliary tract cancers is rapidly evolving, with surgical resection followed by adjuvant chemotherapy being the main treatment option. For advanced disease, chemotherapy is the cornerstone, but targeted therapies for specific gene mutations are showing promising results. Molecular profiling is important for treatment planning and research.
Editorial Material
Hematology
Sigbjorn Berentsen
Article
Hematology
Sigbjorn Berentsen, Wilma Barcellini, Shirley D'Sa, Ulla Randen, Tor Henrik Anderson Tvedt, Bruno Fattizzo, Einar Haukas, Megan Kell, Robert Brudevold, Anders E. A. Dahm, Jakob Dalgaard, Hege Froen, Randi Fykse Hallstensen, Pernille H. Jaeger, Henrik Hjorth-Hansen, Agnieszka Malecka, Markku Oksman, Jurgen Rolke, Mallika Sekhar, Jon Hjalmar Sorbo, Eirik Tjonnfjord, Galina Tsykunova, Geir E. Tjonnfjord
Letter
Hematology
Dennis Lund Hansen, Sigbjorn Berentsen, Bruno Fattizzo, Pernille Lund Hansen, Wilma Barcellini, Henrik Frederiksen
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Hematology
Marit Jalink, Sigbjorn Berentsen, Jorge J. Castillo, Steven P. Treon, Marjan Cruijsen, Bruno Fattizzo, Ramona Cassin, Despina Fotiou, Efstathios Kastritis, Masja De Haas, Liesbeth E. M. Oosten, Henrik Frederiksen, Andrea Patriarca, Shirley D'Sa, Josephine M. I. Vos
Review
Medicine, General & Internal
Sigbjorn Berentsen, Wilma Barcellini
Summary: AIHA is a group of diseases characterized by increased destruction of red cells through autoimmune mechanisms, and recent advancements in diagnosis and treatment have been made. Challenges include wider application of current knowledge, improved understanding of pathogenesis, development of new therapies, and management of refractory cases. Each individual disorder within the AIHA group should be addressed according to their unique differences in cause, pathogenesis, and clinical presentation.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Immunology
Sigbjorn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma
Summary: Sutimlimab, the first complement inhibitor to be extensively studied in cold agglutinin disease, has shown high response rates with low toxicity. The drug appears highly useful in severely anemic patients and in those in whom chemoimmunotherapy is contraindicated or has failed. The choice of therapy in cold agglutinin disease should be individualized.
Review
Hematology
Sigbjorn Berentsen, Geir E. Tjonnfjord
Summary: Cold agglutinin disease can be treated through targeted therapies focusing on clonal B-cell lymphoproliferation and complement-mediated hemolysis. Bendamustine plus rituximab combination and sutimlimab have shown success in treating the disease. Bendamustine-rituximab is effective but slow-acting, while sutimlimab is highly efficacious and acts rapidly with low toxicity.
TRANSFUSION MEDICINE REVIEWS
(2022)
Review
Biotechnology & Applied Microbiology
Georg Gelbenegger, Sigbjorn Berentsen, Bernd Jilma
Summary: Cold agglutinin disease (CAD) is a difficult-to-treat autoimmune hemolytic anemia and B cell lymphoproliferative disorder. This review summarizes clinical and experimental antibody-based treatments for CAD and discusses potential future treatments for CAD.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Article
Hematology
Dennis Lund Hansen, Julien Maquet, Margaux Lafaurie, Soeren Moller, Sigbjorn Berentsen, Henrik Frederiksen, Guillaume Moulis, David Gaist
Summary: The risk of ischemic stroke is higher in the first year after the diagnosis of primary AIHA, according to a binational study using nationwide registers in Denmark and France.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Sarah A. Lau-Braunhut, Hannah Stone, Griffin Collins, Sigbjorn Berentsen, Benjamin S. Braun, Matt S. Zinter
Article
Hematology
Lauren C. Bylsma, Anne Gulbech Ording, Adam Rosenthal, Buket Ozturk, Jon P. Fryzek, Jaime Morales Arias, Alexander Roeth, Sigbjorn Berentsen
Review
Hematology
Sigbjorn Berentsen, Anita Hill, Quentin A. Hill, Tor Henrik Anderson Tvedt, Marc Michel
THERAPEUTIC ADVANCES IN HEMATOLOGY
(2019)
Review
Hematology
Quentin A. Hill, Anita Hill, Sigbjorn Berentsen
Article
Hematology
Oystein Sefland, Ulla Randen, Sigbjorn Berentsen
CASE REPORTS IN HEMATOLOGY
(2019)